KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCA Healthcare (HCA) Other Accumulated Expenses (2016 - 2025)

HCA Healthcare (HCA) has disclosed Other Accumulated Expenses for 16 consecutive years, with $504.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 87.07% to $504.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $504.0 million, a 87.07% decrease, with the full-year FY2025 number at $504.0 million, down 87.07% from a year prior.
  • Other Accumulated Expenses was $504.0 million for Q4 2025 at HCA Healthcare, down from $4.9 billion in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $4.9 billion in Q3 2025 to a low of $361.0 million in Q4 2021.
  • A 5-year average of $3.3 billion and a median of $3.6 billion in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 88.86% in 2021, then surged 891.97% in 2022.
  • HCA Healthcare's Other Accumulated Expenses stood at $361.0 million in 2021, then soared by 891.97% to $3.6 billion in 2022, then increased by 8.1% to $3.9 billion in 2023, then increased by 0.72% to $3.9 billion in 2024, then crashed by 87.07% to $504.0 million in 2025.
  • Per Business Quant, the three most recent readings for HCA's Other Accumulated Expenses are $504.0 million (Q4 2025), $4.9 billion (Q3 2025), and $4.5 billion (Q2 2025).